Advancing Research in Synthetic Drugs and Immunology Therapies

NuvoBio is a wholly owned subsidiary of Zim Corporation (ZIMCF-OTCBB) focused on developing intellectual property and advancing research and development in the areas of new synthetic drugs and Immunotherapies

Through our strategic partnerships and global exclusive licensing agreements with leading drug research institutes and companies, NuvoBio is currently funding research & development projects in key areas including:

  • Implementing unique molecular interaction & analytics using supercomputing technologies to design small peptide drugs that bind to target proteins for cancer therapies and;
  • The development of new and exciting Bi-Specific Immunology therapies for the treatment of kidney cancer

Through our global exclusive licenses, NuvoBio will commercially exploit these new cancer drugs with in-vitro testing beginning in 2016 and in-vivo testing expected to occur in 2017


NuvoBio Corporation
150 Isabella Street
Suite 150
Ottawa, Ontario K1S 1V7

t +1 613-455-0126
f +1 613-727-9868